Global Infectious Disease Therapeutics Market 2019-2023 with Profiles of Major Players - AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi - ResearchAndMarkets.com
Wednesday, 09 January 2019 23:06
Jan. 10, 2019 09:23 UTC

Global Infectious Disease Therapeutics Market 2019-2023 with Profiles of Major Players - AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)-- The "Global Infectious Disease Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The infectious disease therapeutics market will register a CAGR of over 4% by 2023.

Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases.

Increasing prevalence of infectious diseases

There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.

Availability of counterfeit drugs

Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Sanofi, the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures.

AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Antiviral
  • Antibacterial
  • Antifungal
  • Others
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • F. Hoffmann-La Roche
  • Gilead
  • Merck
  • Sanofi

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/9mqnvj/global_infectious?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs


Source: Research and Markets




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter